What is the size and scope of Trulieve's new buyback program?

Trulieve authorized repurchases of up to the lesser of $50 million or 8,495,038 subordinate voting shares. The program is capped at whichever limit is reached first, providing flexibility for execution.

How will Trulieve execute this buyback program?

The filing does not specify the execution mechanism (open-market purchases, Rule 10b-18, accelerated share repurchase, or 10b5-1 plan). The company may provide further details in its Form 10-Q or through subsequent announcements.

Why is Trulieve announcing a buyback now?

The authorization comes after Trulieve's historic NYSE listing as the first U.S. cannabis company to list following federal rescheduling of medical marijuana to Schedule III. With strong free cash flow ($74 million in H1 2026) and $325 million in cash, the company has capacity to return capital to shareholders while positioning for growth in expanding markets like Georgia and Texas.

What does this mean for Trulieve's share count?

At the $50 million authorization limit, the reduction in share count depends on the repurchase price. With ~192 million shares outstanding, a $50 million program could reduce the count by roughly 2–3% if executed at current levels, assuming typical valuations.

Has Trulieve executed any share repurchases to date?

The filing announces the authorization only and does not disclose any executed repurchases. The actual timing and execution of purchases will be at management's discretion, subject to applicable securities regulations and market conditions.

What is the authorization amount relative to Trulieve's cash position?

The $50 million buyback authorization represents roughly 15% of Trulieve's June 30, 2026 cash position of $325 million, leaving substantial liquidity for operations, capital expenditures, and debt service.

TRLV 8-K Filed 2026-08-07 New authorization

Trulieve authorizes $50M share repurchase program

Cannabis company announces buyback up to $50M or 8.5M shares following NYSE listing

Authorization$50M

Authorization (shares)8.5M

MechanismNot specified

What the filing says

Trulieve Cannabis Corp. announced a share repurchase program authorizing buybacks of up to the lesser of $50 million or 8,495,038 subordinate voting shares, according to the company's second-quarter 2026 earnings release filed on August 7, 2026. The authorization represents a capital allocation decision by the NYSE-listed cannabis operator as it navigates post-rescheduling opportunities and cash generation from operations.

The company reported cash flow from operations of $109 million for the first half of 2026 and cash on hand of $325 million as of June 30, 2026. The buyback program was announced alongside the company's Q2 2026 financial results, which showed revenue of $271 million and adjusted EBITDA of $98 million for the quarter. Execution mechanism and timeline for the repurchase program were not specified in the filing.

The authorization comes as Trulieve recently became the first U.S. cannabis company listed on the New York Stock Exchange following federal rescheduling of medical marijuana to Schedule III. The company operates 207 retail dispensaries and 3.5 million square feet of cultivation and processing capacity across multiple states.

Announced share repurchase program up to the lesser of $50 million or 8,495,038 subordinate voting shares. — Trulieve Cannabis Corp. 8-K filing · View on SEC EDGAR →

What this means

The $50 million authorization represents roughly 6.5% of Trulieve's current market equity value and signals management's view that the stock may offer value at current levels. With $325 million in cash and strong free cash flow generation ($74 million in the first half of 2026), the company has financial capacity to execute a buyback without straining operations. The share count is currently around 192 million shares outstanding, so the 8.5 million share cap represents roughly 4.4% of current shares. The program is measured in either dollars or shares, whichever limit is reached first, providing flexibility for execution.

Frequently asked questions

What is the size and scope of Trulieve's new buyback program?: Trulieve authorized repurchases of up to the lesser of $50 million or 8,495,038 subordinate voting shares. The program is capped at whichever limit is reached first, providing flexibility for execution.
How will Trulieve execute this buyback program?: The filing does not specify the execution mechanism (open-market purchases, Rule 10b-18, accelerated share repurchase, or 10b5-1 plan). The company may provide further details in its Form 10-Q or through subsequent announcements.
Why is Trulieve announcing a buyback now?: The authorization comes after Trulieve's historic NYSE listing as the first U.S. cannabis company to list following federal rescheduling of medical marijuana to Schedule III. With strong free cash flow ($74 million in H1 2026) and $325 million in cash, the company has capacity to return capital to shareholders while positioning for growth in expanding markets like Georgia and Texas.
What does this mean for Trulieve's share count?: At the $50 million authorization limit, the reduction in share count depends on the repurchase price. With ~192 million shares outstanding, a $50 million program could reduce the count by roughly 2–3% if executed at current levels, assuming typical valuations.
Has Trulieve executed any share repurchases to date?: The filing announces the authorization only and does not disclose any executed repurchases. The actual timing and execution of purchases will be at management's discretion, subject to applicable securities regulations and market conditions.
What is the authorization amount relative to Trulieve's cash position?: The $50 million buyback authorization represents roughly 15% of Trulieve's June 30, 2026 cash position of $325 million, leaving substantial liquidity for operations, capital expenditures, and debt service.

authorization cannabis-sector nyse-listing execution-mechanism-unspecified

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.